

Faster results, more bone and better healing^{1,2}

GEM 215[®]

Growth-Factor Enhanced Matrix

Promotes rapid healing and new bone formation for dental surgery^{1,5}





Clinically Reliable

Intrabony and Furcation Defects

The largest prospective, randomised, triple-blinded, controlled pivotal clinical trial reported to date using **GEM 21S**° demonstrated the following:

- Stimulated a significant increase in the rate of CAL gain
- Reduced gingival recession at 3 months post-surgery
- Improved bone fill and linear bone gain as compared to a β-TCP bone substitute at 6 months⁸


Recession Defects

A randomised, controlled clinical trial compared **GEM 21S*** to Subepithelial Connective Tissue Grafts (CTG).* Investigators concluded that both the CTG and **GEM 21S*** treatments resulted in clinically significant improvements over the six month evaluation periods and were effective treatments for the correction of recession defects.⁹


Results obtained in this trial are based on a technique not included in the **GEM 215**° Instructions for Use.

Faster results, more bone and better healing^{1,5}

Histologic Evidence







Under polarised light, Sharpey Fibers (SF) are seen inserting into newly regenerated bone (NB) and cementum (NC). In the ground section, well defined connective tissue fibers are also seen inserting into regenerated cementum. PDL = periodontal ligament.9

Overall, rhPDGF-BB
exhibited the greatest
effect size for most parameters,
including clinical attachment
level gain, pocket depth
reduction, less gingival
recession and radiographic
linear bone gain.⁷

GEM 215[®]

Growth-Factor Enhanced Matrix



GEM 21S° is a synthetic bone graft composed of purified, sterile recombinant (bioengineered) platelet-derived growth factor (rhPDGF) and β-TCP. PDGF is naturally found in the body (present in the platelets in your blood) and is often referred to as nature's wound healing protein. **GEM 21S**° increases the amount of PDGF at the grafted site to aid in faster, more bone and better healing.¹

PDGF significantly increases the proliferation and migration of osteoblasts and other cells of the periodontium^{2,3,4}

Consistency

The first and only off-the-shelf source of purified rhPDGF approved for bone and soft tissue regeneration.¹

Cellular Attraction

GEM 21S[®] signals and recruits the specific cells that the body needs to regenerate bone and the surrounding tissues (chemotaxis).⁵

Cellular Proliferation

Once the cells migrate to the site, cell proliferation occurs (mitogenesis). This cellular activity stimulates angiogenesis, resulting in more rapid healing and new bone formation.⁵

Clinical Outcomes

GEM 21S® is one of the most researched growth factors in dentistry. It has been proven to be safe and **effective in regenerating bone and soft tissue** in more than 500 publications and 60+ clinical studies.⁶





How do you

predictability?

Geistlich

Cases by Master Clinicians




Dr. Michael McGuire Houston, TX



Pre-Op



6 month post-op





Pre-Op




6 months post-op



Dr. Robert Levine Philadelphia, PA



Baseline radiograph



Defect dimensions >10mm



Baseline defect



10 year post-op



10 year follow up radiograph

Geistlich

Everything you need for bone regeneration in one partner

At Geistlich, we understand that today's clinical situations require a broad array of product options.

That's why we've expanded our offerings to include quality products which complement the use of the Geistlich regenerative portfolio.

Geistlich Bio-Oss* Collagen

Geistlich Bio-Oss®


Geistlich Bio-Gide®

Geistlich Mucograft®

Geistlich Fibro-Gide®

3D Titanium Scaffold

Yxoss CBR*









GEM 215[®]

Not just for your most challenging cases -GEM 215° brings its best to every case.

500+

Publications

60+

Clinical Studies

1,650

Defects Analysed

~11 months 5 million

Mean Follow-up

Patients Treated

Lynch Biologics LLC, a Geistlich Pharma North America LLC company.

CAUTION: Federal law restricts these devices to sale by or on the order of a dentist or physician. For more information on contraindications, precautions, and directions for use, please refer to the Instructions for Use: https://www.lynchbiologics.com/products/gem-21S/

For more information, please visit: www.geistlich.com/en-au



- GEM 21S' Instructions for Use. Wang HL, et al.: J Periodontol. 1994 May; 65 (5): 429-36. Graves DT. Ann Periodontol. 1997; 2: 259-267. Piche JE, et al.: Bone. 1989; 10(2): 131-189.

- Based on in-vitro and in-vivo data; see device description in GEM 21S package insert for complete information
- Data on file, Lynch Biologics, LLC Lynch SE, Introduction: Tissue Engineering, Applications in Maxillofacial Surgery and Periodontics. Lynch SE, Genco RJ and Marx RE Eds. Quintessence Publishing Co. 1999. Nevins M. et al.: J Periodontol. 2003 Sep; 74(9):1282-92.
- McGuire M, et al.: Int J Periodontics Restorative Dent. 2009; 29:7-21.

GEM 215°

Geistlich Pharma Australia and New Zealand The Zenith, Tower A, Level 21 821 Pacific Highway Chatswood NSW 2067, Australia Phone AU 1800 776 326 Fax AU 1800 709 698 www.geistlich.com/en-au